跳到正文
原文
Endpoints News 生物医药· Drew Armstrong·· 28 天前精选AI 评分70

Post-Hoc Live:美国财政部拟议规则是否终结中国生物药交易?

Post-Hoc Live: Did the US just kill off China biotech deals?

AI 导读

美国财政部周四发布拟议规则以实施2025年COINS法案,将广泛的药物技术列入禁止投资清单。《Endpoints News》执行编辑Drew Armstrong与同事Max Bayer在Post-Hoc Live节目中讨论了该规则的具体内容、对中国生物医药并购交易的潜在影响、行业反应及后续发展。

推荐理由

基于美国财政部拟议规则与COINS法案背景,分析对中国生物医药并购交易的潜在影响及行业反应。

正文 · 原文

Thursday night, the Treasury Department issued a proposed rule to implement the COINS Act, the 2025 law that governs US investment in sensitive technologies in China and other countries. In a surprise turn, a broad set of drug technologies made the list of prohibited investments. China dealmaking has been the backbone of biopharma M&A over the past two years, creating dozens of new companies and partnerships. It’s also been the most divisive issue in biotech, with some arguing for a free flow of drugs, ideas and deals, and others insisting the transactions need to be shut down. On Post-Hoc Live, my colleague Max Bayer and I talked about what the rule says, what it means for biotech, what we know, what we don’t and what happens next. You can watch our conversation on YouTube. You can also listen to the episode on Spotify or Apple Podcasts. We dug into whether the rule will really kill off China deals and how the industry is reacting, and talk about our latest reporting on this fast-developing story. It was a great conversation, and I hope you'll give us a listen. — Drew Armstrong, Executive Editor

来源:Endpoints News 生物医药 · endpoints.news